Protara Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Protara Therapeutics, Inc. (TARA) reported Net Income (Loss) Available to Common Stockholders, Diluted of $26.98 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2022-11-03
- Protara Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2022-09-30 was $7.69M, a 27.42% decline year-over-year.
- Protara Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2022-06-30 was $8.54M, a 34.12% decline year-over-year.
- Protara Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2022-03-31 was $10.76M, a 20.13% decline year-over-year.
- Protara Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-09-30 was $10.60M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2022-09-30 | $7.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $16.23M derived: sum of 2 quarters · filed 2022-11-03 | $26.98M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $8.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $19.29M 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | $10.76M 10-Q · filed 2022-05-05 | |||
| 2021-09-30 | $10.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $23.56M derived: sum of 2 quarters · filed 2022-11-03 | $37.02M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $12.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $26.43M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $13.46M 10-Q · filed 2022-05-05 | |||
| 2014-12-31 | $5.94M 10-K · filed 2016-03-14 | -$1.52M derived: sum of 2 quarters · filed 2016-03-14 | -$5.98M derived: sum of 3 quarters · filed 2016-03-14 | -$10.32M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-09-30 | -$7.46M 10-K · filed 2016-03-14 | -$11.92M derived: sum of 2 quarters · filed 2016-03-14 | -$16.26M derived: sum of 3 quarters · filed 2016-03-14 | -$20.20M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | -$4.46M 10-K · filed 2016-03-14 | -$8.80M derived: sum of 2 quarters · filed 2016-03-14 | -$12.74M derived: sum of 3 quarters · filed 2016-03-14 | -$16.38M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-03-31 | -$4.34M 10-K · filed 2016-03-14 | -$8.28M derived: sum of 2 quarters · filed 2016-03-14 | -$11.92M derived: sum of 3 quarters · filed 2016-03-14 | -$15.00M derived: sum of 4 quarters · filed 2016-03-14 |
| 2013-12-31 | -$3.94M 10-K · filed 2015-03-20 | -$7.58M derived: sum of 2 quarters · filed 2015-03-20 | -$10.65M derived: sum of 3 quarters · filed 2015-03-20 | -$14.03M derived: sum of 4 quarters · filed 2015-03-20 |
| 2013-09-30 | -$3.64M 10-K · filed 2015-03-20 | -$6.72M derived: sum of 2 quarters · filed 2015-03-20 | -$10.09M derived: sum of 3 quarters · filed 2015-03-20 | |
| 2013-06-30 | -$3.07M 10-K · filed 2015-03-20 | -$6.45M derived: sum of 2 quarters · filed 2015-03-20 | ||
| 2013-03-31 | -$3.38M 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |